Perrigo (PRGO) Other Non-Current Assets (2013 - 2026)
Perrigo's (PRGO) quarterly Other Non-Current Assets came in at $264.6 million in Q1 2026, down 12.06% year-on-year from $300.9 million in Q1 2025, and down 2.93% on a QoQ basis from $272.6 million in Q4 2025.
Perrigo (PRGO) Other Non-Current Assets (2013 - 2026) Analysis & Trends
Perrigo (PRGO) has 14 years of Other Non-Current Assets data on file, last reported at $264.6 million in Q1 2026.
- On a quarterly basis, Other Non-Current Assets fell 12.06% year-over-year to $264.6 million in Q1 2026; TTM through Mar 2026 was $264.6 million, a 12.06% decrease from a year earlier, with the FY2025 full-year figure at $272.6 million, down 14.44% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $264.6 million, down from $272.6 million in the prior quarter.
- Over the last five years, Other Non-Current Assets for PRGO reached as high as $541.5 million in Q4 2022 and fell as low as $264.6 million in Q1 2026.
- Historically, Other Non-Current Assets has averaged $341.8 million across 5 years, with a median of $335.2 million in 2023.
- On a YoY basis, Other Non-Current Assets climbed as much as 2183.85% in 2022 and fell as far as 80.44% in 2022.
- Year by year, Other Non-Current Assets stood at $367.7 million in 2022, then slipped by 8.84% to $335.2 million in 2023, then declined by 4.95% to $318.6 million in 2024, then slipped by 14.44% to $272.6 million in 2025, then declined by 2.93% to $264.6 million in 2026.
- Per Business Quant data, the three most recent Other Non-Current Assets figures were $264.6 million in Q1 2026, $272.6 million in Q4 2025, and $280.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 49.22 Mn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 1.79 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 351.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 491.06 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 233.20 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.11 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 73.60 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 295.00 Mn |
| 10 | Perrigo | 1.40 Bn | 1.05 Bn | 325.50 Mn | 264.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 28, 2026 | 264.60 Mn |
| Dec 31, 2025 | 272.60 Mn |
| Sep 27, 2025 | 280.50 Mn |
| Jun 28, 2025 | 301.60 Mn |
| Mar 29, 2025 | 300.90 Mn |
| Dec 31, 2024 | 318.60 Mn |
| Sep 28, 2024 | 299.50 Mn |
| Jun 29, 2024 | 292.30 Mn |
| Mar 30, 2024 | 349.40 Mn |
| Dec 31, 2023 | 335.20 Mn |
| Sep 30, 2023 | 387.30 Mn |
| Jul 1, 2023 | 371.60 Mn |
| Apr 1, 2023 | 342.80 Mn |
| Dec 31, 2022 | 367.70 Mn |
| Oct 1, 2022 | 541.50 Mn |
| Jul 2, 2022 | 408.60 Mn |
| Apr 2, 2022 | 375.70 Mn |
| Dec 31, 2021 | 16.10 Mn |
| Jul 3, 2021 | 2.09 Bn |
| Dec 31, 2020 | 346.80 Mn |